CRISPR Therapeutics (NASDAQ: CRSP)
CRISPR Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CRISPR Therapeutics Company Info
CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.
News & Analysis
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
This biotech's innovative approach could pay rich dividends down the road.
Up 50% in 3 Months, Is This Stock Still a Buy?
This biotech's innovative ways might eventually pay off.
The 3 Things That Matter for CRISPR Therapeutics Now
As time marches on, the factors that could make or break this stock are becoming crystal clear.
3 Monster Stocks in the Making to Buy Right Now
2 Beaten-Down Stocks With Massive Upside Potential
Top ETFs Tracking CRISPR Gene Editing
These exchange-traded funds track companies in this biotech space.
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?
Valuation
Podcast Episodes
"The Era of the Gene-Edited Human Is Here"
An investor's look.
Breaking Down CRISPR Technology
What investors need to know.
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Did China’s “Designer Babies” Just Open Pandora’s Box?
What will this mean for healthcare and for the future of society?
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.